Precision Health Economics’ Scientific Advisor Amitabh Chandra is interviewed on the subject of precision medicine pricing, in a new Q&A for STAT News.
On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.
On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.
Precision for Value thought leader Jeremy Schafer was recently interviewed by BioPharm Insight’s Reynald Castaneda, providing his perspective into projected competition in the biosimilar marketplace.
Precision Medicine Group is proud to announce that precisioneffect has been named one of the top 100 agencies of 2016 by Medical Marketing & Media.
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.
Dan Renick comments on the importance of value demonstration for respiratory disease treatments in The Pink Sheet.
Pharma Industry Firm Moves for More Space
Precision for Value, a company that helps bring pharmaceutical products to market, has found a larger home at One Grand Central Place.
Flemington, N.J., May 19, 2016 – ACT Oncology announced today it has been awarded the Philadelphia Alliance for Capital and Technologies (PACT) 2016 Enterprise Award for Emerging Healthcare companies. The Enterprise Awards, held annually, are the region’s most prestigious business honors for innovative life sciences and technology companies, leaders, and entrepreneurs.
Peter Neumann, Leader in Health Economics and Outcomes Research, Joins Precision Health Economics as Advisor
Los Angeles, May 17, 2016 — Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.